ADVFN US – Market Content Editor
-
Equillium Shares Drop 12.4% After Unveiling Cryptocurrency Treasury Strategy
Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency holdings into its treasury reserve strategy—marking a notable shift away from its core focus on developing treatments for autoimmune and inflammatory diseases. Based in San Diego, Equillium revealed plans to hold digital assets as part of its financial diversification and…
-
GreenPower Shares Rise 5.1% After Winning New Mexico Electric School Bus Pilot Contract
GreenPower Motor Company Inc (NASDAQ:GP) saw its stock jump 5.1% following the announcement that it secured a contract with the state of New Mexico for an all-electric school bus pilot project valued at over $5 million. The two-year pilot program will deploy three Type A all-electric Nano BEAST Access school buses during the 2025-26 school…
-
Vertical Aerospace Shares Rise 4.1% After Strategic Partnership with Aciturri
Vertical Aerospace Ltd (NYSE:EVTL) saw its stock climb 4.1% following the announcement of a long-term strategic agreement with Aciturri Aerostructures to manufacture the airframe for its VX4 electric aircraft. Under the deal, Aciturri will supply the complete airframe for both the pre-production and certified models of Vertical’s electric and hybrid-electric vertical take-off and landing (eVTOL)…
-
Agios Shares Fall 15% After Report of Deaths Among Pyrukynd Patients
Agios Pharmaceuticals stock declined 15% in premarket trading Monday following new entries in the FDA’s Adverse Events Reporting System (FAERS) documenting three deaths in patients treated with Pyrukynd in July. Leerink analyst Andrew Berens, who maintains a market perform rating on Agios, noted that information obtained via a Freedom of Information Act request revealed “two…
-
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status
Dyne Therapeutics Inc (NASDAQ:DYN) stock climbed 3.6% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to its DYNE-251 treatment targeting Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. This designation was granted based on promising data from Dyne’s ongoing DELIVER clinical trial. The breakthrough status offers…
-
D-Wave Quantum Shares Climb 3.7% After Launch of Quantum AI Toolkit
Shares of D-Wave Quantum Inc. (NYSE:QBTS) increased by 3.7% following the company’s announcement of a new suite of tools designed to help developers explore and accelerate advancements in quantum artificial intelligence (AI) and machine learning (ML). The pioneer in quantum computing unveiled an open-source quantum AI toolkit and demonstration that allows developers to seamlessly incorporate…
-
Atlasclear Stock Rockets 50% Following $500K Debenture Investment
Shares of Atlasclear Holdings Inc (AMEX:ATCH) surged by 50% after the company announced a $500,000 debenture investment from Sixth Borough Capital LP, a firm led by Dawson James CEO Robert D. Keyser, Jr. This infusion aligns with Atlasclear’s growth strategy, focused on boosting revenues through expanding broker relationships, ramping up retail operations, and enhancing investment…
-
Hillevax Shares Gain on Acquisition Deal with XOMA Royalty
Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger agreement with XOMA Royalty Corporation (NASDAQ:XOMA), marking the latest in a series of acquisitions by XOMA in the biotech space. According to the agreement, XOMA Royalty will acquire all outstanding shares of Hillevax for $1.95 in cash…
-
LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty
LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA), under which XOMA will acquire LAVA in a cash and milestone-based deal. As outlined in the terms, shareholders of LAVA will receive between $1.16 and $1.24 per share in cash, along with a non-transferable…
-
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light
Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the internal dynamics behind the FDA’s rejection of its skin cancer treatment, RP1. The report, published by STAT, suggested that a high-ranking FDA cancer drug official stepped in late during the review process and influenced the decision—despite…